Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Expected to Announce Earnings of -$0.76 Per Share

Wall Street brokerages forecast that Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) will report ($0.76) earnings per share (EPS) for the current quarter, according to Zacks. Three analysts have made estimates for Lexicon Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.80) and the highest is ($0.71). Lexicon Pharmaceuticals reported earnings of ($0.16) per share in the same quarter last year, which indicates a negative year over year growth rate of 375%. The firm is expected to report its next earnings results on Wednesday, March 11th.

According to Zacks, analysts expect that Lexicon Pharmaceuticals will report full-year earnings of $0.83 per share for the current fiscal year, with EPS estimates ranging from $0.78 to $0.87. For the next financial year, analysts expect that the company will post earnings of ($1.96) per share, with EPS estimates ranging from ($2.40) to ($1.55). Zacks Investment Research’s EPS averages are an average based on a survey of analysts that follow Lexicon Pharmaceuticals.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its earnings results on Thursday, November 7th. The biopharmaceutical company reported $2.11 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.31 by $0.80. Lexicon Pharmaceuticals had a return on equity of 2,372.40% and a net margin of 49.78%. The business had revenue of $294.45 million during the quarter, compared to analyst estimates of $12.00 million. During the same quarter in the previous year, the firm earned ($0.26) EPS. Lexicon Pharmaceuticals’s revenue was up 4124.5% on a year-over-year basis.

A number of brokerages have weighed in on LXRX. Citigroup lowered Lexicon Pharmaceuticals from a “buy” rating to a “neutral” rating and boosted their target price for the stock from $3.00 to $4.00 in a research report on Friday, November 8th. Gabelli raised Lexicon Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.00 target price for the company in a research report on Wednesday, September 11th. ValuEngine raised Lexicon Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, October 2nd. Wedbush reissued a “buy” rating and issued a $17.00 target price on shares of Lexicon Pharmaceuticals in a research report on Monday. Finally, Zacks Investment Research lowered Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, November 16th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and three have given a buy rating to the company’s stock. Lexicon Pharmaceuticals has an average rating of “Hold” and an average target price of $6.45.

NASDAQ:LXRX traded up $0.47 during mid-day trading on Wednesday, reaching $3.77. The company’s stock had a trading volume of 1,995,599 shares, compared to its average volume of 1,297,426. Lexicon Pharmaceuticals has a 12-month low of $1.13 and a 12-month high of $8.39. The firm’s fifty day moving average price is $3.63 and its two-hundred day moving average price is $3.88. The company has a current ratio of 8.11, a quick ratio of 8.01 and a debt-to-equity ratio of 1.42. The stock has a market cap of $400.65 million, a P/E ratio of -3.31 and a beta of 1.00.

In other news, Director Christopher J. Sobecki purchased 25,000 shares of the business’s stock in a transaction on Monday, September 16th. The stock was acquired at an average cost of $2.55 per share, for a total transaction of $63,750.00. Following the purchase, the director now directly owns 112,493 shares in the company, valued at approximately $286,857.15. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Christopher J. Sobecki purchased 99,249 shares of the business’s stock in a transaction on Friday, September 13th. The shares were purchased at an average price of $2.41 per share, with a total value of $239,190.09. Following the completion of the purchase, the director now owns 13,645 shares in the company, valued at $32,884.45. The disclosure for this purchase can be found here. In the last three months, insiders acquired 178,749 shares of company stock valued at $474,560. 6.40% of the stock is owned by insiders.

Several institutional investors have recently added to or reduced their stakes in LXRX. Point72 Asset Management L.P. bought a new stake in shares of Lexicon Pharmaceuticals during the 3rd quarter valued at about $1,590,000. Vanguard Group Inc. grew its stake in shares of Lexicon Pharmaceuticals by 8.1% during the 2nd quarter. Vanguard Group Inc. now owns 4,240,111 shares of the biopharmaceutical company’s stock valued at $26,670,000 after purchasing an additional 319,382 shares during the period. Wedbush Securities Inc. grew its stake in shares of Lexicon Pharmaceuticals by 105.1% during the 3rd quarter. Wedbush Securities Inc. now owns 398,684 shares of the biopharmaceutical company’s stock valued at $1,200,000 after purchasing an additional 204,345 shares during the period. First Manhattan Co. grew its stake in shares of Lexicon Pharmaceuticals by 7.3% during the 2nd quarter. First Manhattan Co. now owns 2,949,979 shares of the biopharmaceutical company’s stock valued at $18,555,000 after purchasing an additional 201,393 shares during the period. Finally, Virtus ETF Advisers LLC bought a new stake in shares of Lexicon Pharmaceuticals during the 2nd quarter valued at about $901,000. Institutional investors and hedge funds own 96.27% of the company’s stock.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.

Further Reading: What impact do institutional investors have on markets?

Get a free copy of the Zacks research report on Lexicon Pharmaceuticals (LXRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.